Table 2. Treatment-related adverse events that occurred during immunotherapy.

AEs	Grade 1, n (%)	Grade 2, n (%)	Grade 3, n (%)	Grade 4	Grade 5
Fatigue	1 (0.5)	–	–	–	–
Rash	4 (1.9)	4 (1.9)	1 (0.5)	–	–
Vomit	3 (1.4)	–	–	–	–
Diarrhea	1 (0.5)	–	–	–	–
Anemia	–	2 (0.9)	–	–	–
Granulocytopenia	2 (0.9)	4 (1.9)	3 (1.4)	–	–
Thrombocytopenia	–	1 (0.5)	2 (0.9)	–	–
Hypothyroidism	5 (2.3)	2 (0.9)	–	–	–
Hyperthyroidism	1 (0.5)	–	–	–	–
Increased AST/ALT	7 (3.2)	2 (0.9)	1 (0.5)	–	–
Increased creatinine	3 (1.4)	1 (0.5)	–	–	–
Pneumonitis	1 (0.5)	9 (4.2)	3 (1.4)	–	–
Encephalitis	–	1 (0.5)	–	–	–
Ostealgia	1 (0.5)	–	–	–	–
Pyrexia	–	1 (0.5)	–	–	–
Nausea	3 (1.4)	–	–	–	–
Leukopenia	4 (1.9)	4 (1.9)	4 (1.9)	–	–
Hematochezia	1 (0.5)	–	–	–	–
Cutaneous hemangioma	2 (0.9)	2 (0.9)	1 (0.5)	–	–
Myocarditis	1 (0.5)	–	–	–	–

AE, adverse event; AST, aspartate transaminase; ALT, alanine aminotransferase.